Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Pres

- Longer-term follow-up data demonstrate consistent and durable response to treatment -BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced two oral presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition from the global pivotal trials of CASGEVY...

Related Keywords

Saudi Arabia ,United Kingdom ,London ,City Of ,United States ,Boston ,Massachusetts ,Bahrain ,Australia ,Great Britain ,Saudi ,American ,America ,Manisha Pai ,Heather Nichols ,Exagamglogene Autotemcel ,Carmen Bozic ,Occlusive Crisis On Health ,National Health Regulatory Authority ,Facebook ,Drug Administration ,Regulatory Agency ,Improvements In Health ,Vertex Pharmaceuticals Incorporated ,Drug Agency ,Linkedin ,Companies To Work ,Exchange Commission ,European Medicines Agency ,Vertex Pharmaceuticals Incorporated Nasdaq ,Instagram ,Youtube ,American Society Of Hematology ,Global Medicines Development ,American Society ,Annual Meeting ,Executive Vice President ,Medical Affairs ,Chief Medical Officer ,Prescription Drug User Fee Act ,Severe Sickle Cell ,Health Related Quality ,Life After Exagamglogene Autotemcel ,Transfusion Dependent Beta ,Patients With Severe Sickle Cell ,Status Among Patients ,Cohort Study ,Recent Vaso Occlusive Crisis ,Sickle Cell ,Sickle Cell Disease Prevalence ,Model Using ,Foreign Born State Specific Population ,Sickle Cell Disease ,Transfusion Dependent Beta Thalassemia ,Saudi Food ,Prescribing Information ,Patient Information ,North America ,Top Employers ,Private Securities Litigation Reform Act ,